JAMA Network
About The Study: Ivermectin-benzimidazole prescribing rose rapidly following celebrity endorsement in January 2025, with disproportionate increases among male patients, white patients, residents of the U.S. South, and individuals with cancer. The elevated prescribing observed among patients with cancer is particularly concerning; individuals facing life-threatening illness may delay or forgo conventional treatments in favor of unproven therapies, potentially allowing their disease to progress.
/Public Release. This material from the originating organization/author(s) might be of the point-in-time nature, and edited for clarity, style and length. Mirage.News does not take institutional positions or sides, and all views, positions, and conclusions expressed herein are solely those of the author(s).View in full here.
